These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 33347943)

  • 1. Design and Testing of a Cabotegravir Implant for HIV Prevention.
    Karunakaran D; Simpson SM; Su JT; Bryndza-Tfaily E; Hope TJ; Veazey R; Dobek G; Qiu J; Watrous D; Sung S; Chacon JE; Kiser PF
    J Control Release; 2021 Feb; 330():658-668. PubMed ID: 33347943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.
    Markowitz M; Frank I; Grant RM; Mayer KH; Elion R; Goldstein D; Fisher C; Sobieszczyk ME; Gallant JE; Van Tieu H; Weinberg W; Margolis DA; Hudson KJ; Stancil BS; Ford SL; Patel P; Gould E; Rinehart AR; Smith KY; Spreen WR
    Lancet HIV; 2017 Aug; 4(8):e331-e340. PubMed ID: 28546090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cabotegravir long-acting for HIV-1 prevention.
    Andrews CD; Heneine W
    Curr Opin HIV AIDS; 2015 Jul; 10(4):258-63. PubMed ID: 26049951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultra-long-acting in-situ forming implants with cabotegravir protect female macaques against rectal SHIV infection.
    Young IC; Massud I; Cottrell ML; Shrivastava R; Maturavongsadit P; Prasher A; Wong-Sam A; Dinh C; Edwards T; Mrotz V; Mitchell J; Seixas JN; Pallerla A; Thorson A; Schauer A; Sykes C; De la Cruz G; Montgomery SA; Kashuba ADM; Heneine W; Dobard CW; Kovarova M; Garcia JV; García-Lerma JG; Benhabbour SR
    Nat Commun; 2023 Feb; 14(1):708. PubMed ID: 36759645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study.
    Orkin C; Oka S; Philibert P; Brinson C; Bassa A; Gusev D; Degen O; García JG; Morell EB; Tan DHS; D'Amico R; Dorey D; Griffith S; Thiagarajah S; St Clair M; Van Solingen-Ristea R; Crauwels H; Ford SL; Patel P; Chounta V; Vanveggel S; Cutrell A; Van Eygen V; Vandermeulen K; Margolis DA; Smith KY; Spreen WR
    Lancet HIV; 2021 Apr; 8(4):e185-e196. PubMed ID: 33794181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial.
    Murray MI; Markowitz M; Frank I; Grant RM; Mayer KH; Hudson KJ; Stancil BS; Ford SL; Patel P; Rinehart AR; Spreen WR; Margolis DA
    HIV Clin Trials; 2018 Aug; 19(4):129-138. PubMed ID: 30445896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Subcutaneous Implant of Tenofovir Alafenamide Fumarate Causes Local Inflammation and Tissue Necrosis in Rabbits and Macaques.
    Su JT; Simpson SM; Sung S; Tfaily EB; Veazey R; Marzinke M; Qiu J; Watrous D; Widanapathirana L; Pearson E; Peet MM; Karunakaran D; Grasperge B; Dobek G; Cain CM; Hope T; Kiser PF
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31871073
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial.
    Landovitz RJ; Li S; Eron JJ; Grinsztejn B; Dawood H; Liu AY; Magnus M; Hosseinipour MC; Panchia R; Cottle L; Chau G; Richardson P; Marzinke MA; Eshleman SH; Kofron R; Adeyeye A; Burns D; Rinehart AR; Margolis D; Cohen MS; McCauley M; Hendrix CW
    Lancet HIV; 2020 Jul; 7(7):e472-e481. PubMed ID: 32497491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults.
    Letendre SL; Mills A; Hagins D; Swindells S; Felizarta F; Devente J; Bettacchi C; Lou Y; Ford S; Sutton K; Shaik JS; Crauwels H; D'Amico R; Patel P
    J Antimicrob Chemother; 2020 Mar; 75(3):648-655. PubMed ID: 31873746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multicompartmental pharmacokinetic evaluation of long-acting cabotegravir in healthy adults for HIV preexposure prophylaxis.
    Shaik JS; Weld ED; Edick S; Fuchs E; Riddler S; Marzinke MA; D'Amico R; Bakshi K; Lou Y; Hendrix C; Han K; Ford SL; Margolis D; Spreen W; Patel P
    Br J Clin Pharmacol; 2022 Feb; 88(4):1667-1678. PubMed ID: 34240467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese Men.
    Han K; Wannamaker P; Lu H; Zhu B; Wang M; Paff M; Spreen WR; Ford SL
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0205721. PubMed ID: 35129374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and Drug-Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine.
    Hodge D; Back DJ; Gibbons S; Khoo SH; Marzolini C
    Clin Pharmacokinet; 2021 Jul; 60(7):835-853. PubMed ID: 33830459
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
    Margolis DA; Brinson CC; Smith GHR; de Vente J; Hagins DP; Eron JJ; Griffith SK; Clair MHS; Stevens MC; Williams PE; Ford SL; Stancil BS; Bomar MM; Hudson KJ; Smith KY; Spreen WR;
    Lancet Infect Dis; 2015 Oct; 15(10):1145-1155. PubMed ID: 26201299
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Formulation and pharmacology of long-acting cabotegravir.
    Trezza C; Ford SL; Spreen W; Pan R; Piscitelli S
    Curr Opin HIV AIDS; 2015 Jul; 10(4):239-45. PubMed ID: 26049948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Rifampin on the Single-Dose Pharmacokinetics of Oral Cabotegravir in Healthy Subjects.
    Ford SL; Sutton K; Lou Y; Zhang Z; Tenorio A; Trezza C; Patel P; Spreen W
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28739783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cabotegravir: The first long-acting injectable for HIV pre-exposure prophylaxis.
    Prather C; Jeon C
    Am J Health Syst Pharm; 2022 Oct; 79(21):1898-1905. PubMed ID: 35894204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A literature review of the patent application publications on cabotegravir - an HIV integrase strand transfer inhibitor.
    Kovač L; Časar Z
    Expert Opin Ther Pat; 2020 Mar; 30(3):195-208. PubMed ID: 31944142
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacokinetic testing of a first-generation cabotegravir prodrug in rhesus macaques.
    McMillan J; Szlachetka A; Zhou T; Morsey B; Lamberty B; Callen S; Gautam N; Alnouti Y; Edagwa B; Gendelman HE; Fox HS
    AIDS; 2019 Mar; 33(3):585-588. PubMed ID: 30289818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiparametric magnetic resonance imaging to characterize cabotegravir long-acting formulation depot kinetics in healthy adult volunteers.
    Jucker BM; Fuchs EJ; Lee S; Damian V; Galette P; Janiczek R; Macura KJ; Jacobs MA; Weld ED; Solaiyappan M; D'Amico R; Shaik JS; Bakshi K; Han K; Ford S; Margolis D; Spreen W; Gupta MK; Hendrix CW; Patel P
    Br J Clin Pharmacol; 2022 Feb; 88(4):1655-1666. PubMed ID: 34240449
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cabotegravir in the treatment and prevention of Human Immunodeficiency Virus-1.
    McPherson TD; Sobieszczyk ME; Markowitz M
    Expert Opin Investig Drugs; 2018 Apr; 27(4):413-420. PubMed ID: 29633869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.